Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Sabrina L Browning, MD, Terri L Parker, MD, Noffar Bar, MD, Stuart Seropian, MD, Alfred I Lee, MD PhD, Tara Anderson, PA, Natalia Neparidze, MD

Blood (2019) 134 (Supplement_1): 5569.

https://doi.org/10.1182/blood-2019-130134

Published: 2019

Journal Articles

Ruxolitinib and Steroid Refractory/Dependent Bronchiolitis Obliterans after Hematopoietic Cell Transplantation: A Steroid Sparing Agent That Also Resulted in Improved Lung Function in Children

Michelle Schoettler, MD, Meera Subramaniam, MD, Steven P. Margossian, MD PhD

Blood (2018) 132 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2018-99-114971

Published: 2018

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd

Blood (2018) 132 (Supplement 1): 3246.

https://doi.org/10.1182/blood-2018-99-112764

Published: 2018

Journal Articles

A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion

Ali McBride, PharmD,MS, Muhammad Usman, MD, Muhammad Jahanzeb Khalil, MD, Muhammad Junaid Tariq, MD, Muhammad Asad Fraz, MD, Awais Ijaz, MD, Malik Qistas Ahmad, MD MBBS, Ali Younas Khan, MD, Sharoon Samuel, MD, Insija Ilyas Selene, MBBS, James Camamo, Cara Chang, PharmD, Jemin Aby Jose, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5667.

https://doi.org/10.1182/blood-2018-99-119736

Published: 2018

Journal Articles

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Issam S. Hamadeh, PharmD, Justin Arnall, Pharm.D., Ekaterina Kachur, PharmD, Allison Martin, PharmD, Megan Helena Jagosky, MD, Reed Friend, MD, Shebli Atrash, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 2255.

https://doi.org/10.1182/blood-2018-99-118737

Published: 2018

Journal Articles

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Ajai Chari, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Hareth Nahi, MD PhD, Jie Tang, Peter Hellemans, Brenda Tromp, MSc, Pamela L Clemens, PhD, Andrew Farnsworth, Jesus F San-Miguel, MD PhD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 1995.

https://doi.org/10.1182/blood-2018-99-113590

Published: 2018

Journal Articles

Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial

Maria José Cejalvo, Mario Legarda, Eugenia Abella, Elena Cabezudo, Cristina Encinas, Ana García-Feria, Belén Iñigo, Jesús Marín, Paz Ribas, M. Ángeles Ruíz, Javier de la Rubia

Blood (2017) 130 (Supplement 1): 1866.

https://doi.org/10.1182/blood.V130.Suppl_1.1866.1866

Published: 2017

Journal Articles

the Efficacy of Extra-Corporal Photopheresis for Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: A Retrospective, Matched, Case-Control Study

Mehrdad Hefazi, MD, Kimberly J. Langer, D.N.P., C.N.P., Alli Louise McClanahan, CNP, Jeffrey L. Winters, MD, Dennis A. Gastineau, MD, Eapen K. Jacob, MD, Justin D. Kreuter, Manish Gandhi, MD, William J. Hogan, MBBCh, Mark R. Litzow, MD, Shahrukh K. Hashmi, MDMPH, Vivek N Iyer, MD, Rodrigo Cartin-Ceba, MD, Mrinal M. Patnaik, MDMBBS

Blood (2017) 130 (Supplement 1): 4500.

https://doi.org/10.1182/blood.V130.Suppl_1.4500.4500

Published: 2017

Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD

Blood (2017) 130 (Supplement 1): 1839.

https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839

Published: 2017

Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1149.

https://doi.org/10.1182/blood.V128.22.1149.1149

Published: 2016

Journal Articles

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

Ajai Chari, MD, Tomer M Mark, MD MSc, Amrita Krishnan, Keith Stockerl-Goldstein, Saad Z Usmani, MD FACP, Anil Londhe, Delores Etheredge, Hollee Parros, Sarah Fleming, Baolian Liu, Scott Freeman, Jon Ukropec, PhD, Thomas Lin, Ajay K Nooka, MD MPH

Blood (2016) 128 (22): 2142.

https://doi.org/10.1182/blood.V128.22.2142.2142

Published: 2016

Journal Articles

A Rapid Desensitization Program Is a Viable Therapeutic Option in the Management of Immunomodulating Agent-Related Hypersensitivity Reactions in Patients with Plasma Cell Disorders

Jack T Seki, PharmD, Naoko Sakurai, Phm, MSc, Wallace Lam, BSc, Phm, Vesna Lukaroska, BSc, Phm, Anna Granic, BSc, Phm, Patricia Disperati, MD, Amy Tam, MD, Suzanne Trudel, MD, Donna Reece, MD

Blood (2016) 128 (22): 2411.

https://doi.org/10.1182/blood.V128.22.2411.2411

Published: 2016

Journal Articles

Colchicine Can be an Effective Adjunctive Treatment for Extensive Refractory Chronic-Graft-Versus-Host Disease

Sandy W. Wong, MD, Raymond L. Comenzo, MD, Todd F. Roberts, MD MSC, FRCP (C), Kellie Sprague, MD, Kenneth B. Miller, MD

Blood (2015) 126 (23): 5461.

https://doi.org/10.1182/blood.V126.23.5461.5461

Published: 2015

Journal Articles

Modulation of Leukotriene Signaling Affecting Cell Growth in Chronic Myeloid Leukemia: A Key Pathway to Cure?

Elham Yektaei, PhD, Anders Nilsson, PhD, Barbro Näsman-Glaser, MSc, Marja Ekblom, MD PhD, Hong Qian, PhD, Olof Rådmark, PhD, Ana Zovko, PhD, Lena Kanter, MD PhD, Jonas Wallvik, MD PhD, Leif Stenke, MD PhD

Blood (2015) 126 (23): 5137.

https://doi.org/10.1182/blood.V126.23.5137.5137

Published: 2015

Journal Articles

Thrombotic Microangiopathy (TMA) and Other Severe Systemic Reactions Caused By Quinine-Containing Beverages: Report of a Patient and Review of Published Reports

Jordan M Morton, MD, Evaren E Page, MPH, Nathan W Liles, MD MPH, James N. George, MD

Blood (2015) 126 (23): 4651.

https://doi.org/10.1182/blood.V126.23.4651.4651

Published: 2015

Journal Articles

Similarities and Differences in Signal Transduction and Crosstalk of the G Protein-Coupled Receptors CXCR4 and CysLT1 in CD34+ Hematopoietic Stem/Progenitor Cells,

Adriana C Drost, Ute Krauß, Lothar Kanz, MD, Robert Möhle

Blood (2011) 118 (21): 3392.

https://doi.org/10.1182/blood.V118.21.3392.3392

Published: 2011

Journal Articles

Cysteinyl Leukotrienes Signal Via Overexpressed CysLT1, but Not CysLT2 Receptor In Chronic Lymphocytic Leukemia

Adriana Drost, Mirjam Funk, Karoline Norz, Anne Zipfel, Lothar Kanz, Robert Mohle

Blood (2010) 116 (21): 3612.

https://doi.org/10.1182/blood.V116.21.3612.3612

Published: 2010

Journal Articles

The G Protein-Coupled Receptor cysLT1 Mediates G i Protein-Dependent Chemotaxis and Adhesion of CD34+ Cells in Vitro Similar to CXCR4, but Not Progenitor Mobilization in Vivo .

Adriana Drost, PhD, Lena Jaggy, Lothar Kanz, MD, Robert Möhle, MD

Blood (2008) 112 (11): 1388.

https://doi.org/10.1182/blood.V112.11.1388.1388

Published: 2008

Journal Articles

Presence of Alpha Thalassemia Trait Complicating the Diagnosis of Polycythemia Vera in a Pediatric Patient.

Shannon L. Carpenter, MD, Howard A. Britton, MD, Josef T. Prchal, MD, Martha P. Mims, MD, PhD

Blood (2005) 106 (11): 3847.

https://doi.org/10.1182/blood.V106.11.3847.3847

Published: 2005

NARROW

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Ruxolitinib and Steroid Refractory/Dependent Bronchiolitis Obliterans after Hematopoietic Cell Transplantation: A Steroid Sparing Agent That Also Resulted in Improved Lung Function in Children

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Consolidation with a Short Course of Daratumumab Improves Complete Response Rates in Patients with AL Amyloidosis or Lcdd

A Single Center Retrospective Evaluation of Daratumumab Infusion Related Reactions with Split-First Dose Day 1 and Day 2 Infusion

Rapid Infusion Daratumumab Is Safe and Well Tolerated in Clinical Practice

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Activity and Safety of Daratumumab Monotheray in Patients with Relapsed and Refractory Multiple Myeloma Requiring Dialysis: Preliminary Results of Spanish, Retrospective, Multicenter Trial

the Efficacy of Extra-Corporal Photopheresis for Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: A Retrospective, Matched, Case-Control Study

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Myeloma

A Rapid Desensitization Program Is a Viable Therapeutic Option in the Management of Immunomodulating Agent-Related Hypersensitivity Reactions in Patients with Plasma Cell Disorders

Colchicine Can be an Effective Adjunctive Treatment for Extensive Refractory Chronic-Graft-Versus-Host Disease

Modulation of Leukotriene Signaling Affecting Cell Growth in Chronic Myeloid Leukemia: A Key Pathway to Cure?

Thrombotic Microangiopathy (TMA) and Other Severe Systemic Reactions Caused By Quinine-Containing Beverages: Report of a Patient and Review of Published Reports

Similarities and Differences in Signal Transduction and Crosstalk of the G Protein-Coupled Receptors CXCR4 and CysLT1 in CD34+ Hematopoietic Stem/Progenitor Cells,

Cysteinyl Leukotrienes Signal Via Overexpressed CysLT1, but Not CysLT2 Receptor In Chronic Lymphocytic Leukemia

The G Protein-Coupled Receptor cysLT1 Mediates G i Protein-Dependent Chemotaxis and Adhesion of CD34+ Cells in Vitro Similar to CXCR4, but Not Progenitor Mobilization in Vivo .

Presence of Alpha Thalassemia Trait Complicating the Diagnosis of Polycythemia Vera in a Pediatric Patient.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only